Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy (Q24186051)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

meta-analysis

0 references

title

Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

0 references

3

Leontien C M Kremer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Elvira C van Dalen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

Helena J H van der Pal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

publication date

3 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

CD005008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group

9 March 2020

cites work

1 reference

12 December 2020

Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

1 reference

12 December 2020

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

1 reference

12 December 2020

Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules

1 reference

12 December 2020

Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study

1 reference

12 December 2020

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

1 reference

12 December 2020

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

1 reference

12 December 2020

Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.

1 reference

12 December 2020

Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients

1 reference

12 December 2020

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

1 reference

12 December 2020

Quantifying the amount of variation in survival explained by prostate-specific antigen

1 reference

12 December 2020

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

1 reference

12 December 2020

Echocardiographic evaluation of acute cardiotoxicity in the treatment of Hodgkin disease according to the German Hodgkin's Lymphoma Study Group

1 reference

12 December 2020

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

12 December 2020

Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers

1 reference

12 December 2020

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

1 reference

12 December 2020

Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy

1 reference

12 December 2020

Does anthracycline administration by infusion in children affect late cardiotoxicity?

1 reference

12 December 2020

Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review

1 reference

12 December 2020

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

1 reference

12 December 2020

Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma

1 reference

12 December 2020

Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function

1 reference

12 December 2020

A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.

1 reference

12 December 2020

Cardiotoxicity of cancer chemotherapy: implications for children

1 reference

12 December 2020

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

12 December 2020

Anticancer agents and cardiotoxicity

1 reference

12 December 2020

Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study

1 reference

12 December 2020

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

1 reference

12 December 2020

Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML

1 reference

12 December 2020

Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).

1 reference

12 December 2020

Early and late arrhythmogenic effects of doxorubicin

1 reference

12 December 2020

Adjuvant chemotherapy for high-risk operable breast cancer

1 reference

12 December 2020

Evaluation of longitudinal ventricular function with tissue Doppler echocardiography in children treated with anthracyclines

1 reference

12 December 2020

Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia

1 reference

12 December 2020

An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

1 reference

12 December 2020

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

1 reference

12 December 2020

New anthracycline antitumor antibiotics

1 reference

12 December 2020

A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors

1 reference

12 December 2020

Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.

1 reference

12 December 2020

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy

1 reference

12 December 2020

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

12 December 2020

Different anthracycline derivates for reducing cardiotoxicity in cancer patients

1 reference

12 December 2020

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study

1 reference

12 December 2020

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

1 reference

12 December 2020

The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia

1 reference

12 December 2020

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809

1 reference

12 December 2020

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

1 reference

12 December 2020

Cardioprotective interventions for cancer patients receiving anthracyclines

1 reference

12 December 2020

Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial.

1 reference

12 December 2020

High risk of symptomatic cardiac events in childhood cancer survivors

1 reference

12 December 2020

Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer

1 reference

12 December 2020

Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation

1 reference

12 December 2020

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes

1 reference

12 December 2020

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

1 reference

12 December 2020

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

1 reference

12 December 2020

Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer

1 reference

12 December 2020

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer

1 reference

12 December 2020

Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma

1 reference

12 December 2020

4'Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma

1 reference

12 December 2020

Tolerance of 24-hour infusions or low- and high-dose bolus injections of adriamycin in children

1 reference

12 December 2020

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma

1 reference

12 December 2020

Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report

1 reference

12 December 2020

Cardiac toxicity of daunorubicin

1 reference

12 December 2020

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

12 December 2020

Adriamycin and Cytoxan in the treatment of inoperable lung cancer

1 reference

12 December 2020

Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study

1 reference

12 December 2020

Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy

1 reference

12 December 2020

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

1 reference

12 December 2020

Anthracycline cardiomyopathy monitored by morphologic changes

1 reference

12 December 2020

Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study

1 reference

12 December 2020

Randomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial

1 reference

12 December 2020

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

1 reference

12 December 2020

An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer

1 reference

12 December 2020

[Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)]

1 reference

12 December 2020

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

12 December 2020

Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: interim analysis of a prospective randomized trial

1 reference

12 December 2020

Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol

1 reference

12 December 2020

Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies

1 reference

12 December 2020

Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration

1 reference

12 December 2020

Dose response evaluation of adriamycin in human neoplasia

1 reference

12 December 2020

Anthracycline-induced cardiotoxicity

1 reference

12 December 2020

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

12 December 2020

Epirubicin cardiotoxicity: a study comparing low- with high-dose-intensity weekly schedules

1 reference

12 December 2020

Paclitaxel and epirubicin as first-line therapy for patients with metastatic breast cancer

1 reference

12 December 2020

Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.

1 reference

12 December 2020

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer

1 reference

12 December 2020

Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer

1 reference

12 December 2020

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

12 December 2020

Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration

1 reference

12 December 2020

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

1 reference

12 December 2020

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

12 December 2020

10.1002/14651858.CD005008.PUB4

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

4476975

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

4476975

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26938118 AND SRC:MED&resulttype=core&format=json

9 March 2020

PubMed publication ID

26938118

2 references

Consolidated OpenCitations Corpus – April 2017

4476975